VIENNA, Austria, May 21 /PRNewswire/ -- EUCODIS Bioscience, a company developing, manufacturing, and marketing enzymes and other proteins for the chemical industry, announced today that it has entered into a research agreement with Genencor, a division of Danisco. Under the terms of the agreement, EUCODIS Bioscience will apply its proprietary, patent-protected technology of "in vivo recombination" to the development of an optimized version of an undisclosed enzyme. The Company will generate a library of recombinants of the enzyme, and Genencor will screen the library for clones (enzymes) with desired product profiles.
"We are pleased that Genencor, a leading enzyme manufacturer and one of the largest biotechnology companies worldwide, has chosen EUCODIS Bioscience as a partner", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "In previous development programs - both for our own portfolio of commercial enzymes and for industrial partners - our technology of in vivo recombination has reliably shown its capacity to generate high-quality libraries of active enzymes with significant improvement of the desired activities in a single cycle of recombination."
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.
EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.
EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.
CONTACT: Company contact EUCODIS Bioscience: Rudy Pandjaitan, PhD, CEO,
EUCODIS Bioscience, Brunner Strasse 59, 1230 VIENNA, AUSTRIA,
+43-1-86634-9241, firstname.lastname@example.org; Media contact EUCODIS
Bioscience: Frank Butschbacher, Investor Relations & Communications,
http://www.butschbacher.net, +43-650-7844940, email@example.com